GO
Loading...

AstraZeneca PLC

More

  • AstraZeneca steps up push into cancer immunotherapy Thursday, 31 Jul 2014 | 8:51 AM ET

    LONDON, July 31- AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. AstraZeneca said it would present further data looking at MEDI4736 in lung cancer, as well as early results for head and neck cancer, in September at the annual meeting of the European Society for Medical Oncology.

  • *Investors focused on possible Pfizer return. LONDON, July 31- AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • DUBLIN, July 30- Ireland is in the firing line from Washington again for luring U.S. companies to its shores for tax benefits, but despite contrite noises coming from Dublin, it has too much to lose to discourage U.S. firms bent on shifting their tax domiciles.

  • *Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

  • LONDON, July 30- AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

  • AstraZeneca announces Almirall deal worth up to $2.1B Wednesday, 30 Jul 2014 | 2:24 AM ET

    AstraZeneca took steps to build up its respiratory medicine business by striking a deal to acquire the rights to lung drugs developed by Almirall.

  • LONDON, July 30- AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion to acquire the rights to lung drugs developed by Spain's Almirall.

  • Pharma CEOs: Tax system flaws help overseas rivals Tuesday, 29 Jul 2014 | 1:35 PM ET
    Ian Read, CEO, Pfizer,  leaves the House of Commons on May 14, 2014 in London.

    Pfizer CEO Ian Read also says a potential U.S. tax holiday would be only a temporary solution.

  • July 29- Pfizer Inc, which in May abandoned its $118 billion bid to buy AstraZeneca Plc, on Tuesday left investors guessing whether it would renew its pursuit of its British rival, but said it was considering other deals. Under UK takeover rules, AstraZeneca can attempt to re-engage with Pfizer in August, and Pfizer can make another run at AstraZeneca in November.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 10:54 AM ET

    Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • How banks are cashing in on tax-evading mergers Tuesday, 29 Jul 2014 | 8:29 AM ET
    Jamie Dimon

    Investment banks have collected, or will soon collect, $1B in fees to help American companies "move" abroad. NYT reports.

  • UPDATE 1-Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:51 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.

  • Pfizer's 2Q profit sinks 79 pct but tops forecasts Tuesday, 29 Jul 2014 | 7:37 AM ET

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion- plus gain from a business spinoff.

  • Merck 2Q profit more than doubles Tuesday, 29 Jul 2014 | 7:28 AM ET

    The maker of popular Type 2 diabetes pill Januvia said Tuesday that net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:28 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • BEIJING, July 28- Microsoft Corp appears to be the latest U.S. company targeted by China for anti-trust investigation after government officials paid sudden visits to the software firm's Chinese offices on Monday.

  • Pfizer's need for deal looms with earnings report Monday, 28 Jul 2014 | 7:12 AM ET

    Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.